SecBot SecBot
SECBOTREPLAY Home › Report › CLDX

CLDX · Celldex reported Q1 2026 EPS of -$1.18, missing consensus of -$1.07 by…

Celldex Therapeutics, Inc. · PRESS-RELEASE filed Jun 14, 2026 at 10:21 ET

At the news

BEARISHIMPACT 6/10

PRESS-RELEASE filed Jun 14, 2026 at 10:21 ET

Celldex reported Q1 2026 EPS of -$1.18, missing consensus of -$1.07 by 10.8%. The press release focuses on positive long-term Phase 2 data for barzolvolimab in CSU, showing durable angioedema improvements off-treatment through Week 76. Phase 3 topline data is expected in Q4 2026, with a BLA submission planned for 2027.

  • Q1 2026 EPS of -$1.18 missed consensus of -$1.07 (-10.8% miss)
  • Revenue of $859K (consensus $859K), in line
  • Phase 2 barzolvolimab data showed up to 64% of angioedema patients remained symptom-free 7 months after last dose
  • Phase 3 CSU trials fully enrolled with 1,939 patients; topline data expected Q4 2026

Replay the market's reaction

Step through every 5 minutes around the news, then see how it compares with similar events.

Subscribe for Full Access